BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12428733)

  • 21. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs.
    Zucker M; Weizman A; Harel D; Rehavi M
    Neuropsychobiology; 2001; 44(4):187-91. PubMed ID: 11702019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
    Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
    Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
    J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Tillerson JL; Caudle WM; Reverón ME; Miller GW
    Exp Neurol; 2002 Nov; 178(1):80-90. PubMed ID: 12460610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
    Ekue A; Boulanger JF; Morissette M; Di Paolo T
    J Neuroendocrinol; 2002 Sep; 14(9):731-6. PubMed ID: 12213134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.
    Harrington KA; Augood SJ; Kingsbury AE; Foster OJ; Emson PC
    Brain Res Mol Brain Res; 1996 Feb; 36(1):157-62. PubMed ID: 9011752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.
    Colebrooke RE; Humby T; Lynch PJ; McGowan DP; Xia J; Emson PC
    Eur J Neurosci; 2006 Nov; 24(9):2622-30. PubMed ID: 17100850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
    Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
    Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Biogenic Amine Transporters in Trace Amine-Associated Receptor 1 Regulation of Methamphetamine-Induced Neurotoxicity.
    Miner NB; Phillips TJ; Janowsky A
    J Pharmacol Exp Ther; 2019 Oct; 371(1):36-44. PubMed ID: 31320495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice.
    Hall FS; Sora I; Uhl GR
    Neuropsychopharmacology; 2003 Apr; 28(4):620-8. PubMed ID: 12655306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.
    Stephenson DT; Childs MA; Li Q; Carvajal-Gonzalez S; Opsahl A; Tengowski M; Meglasson MD; Merchant K; Emborg ME
    Cell Transplant; 2007; 16(3):229-44. PubMed ID: 17503735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
    German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
    Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations.
    Hogan KA; Staal RG; Sonsalla PK
    J Neurochem; 2000 May; 74(5):2217-20. PubMed ID: 10800969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice.
    Cleren C; Vilpoux C; Dourmap N; Bonnet JJ; Costentin J
    Brain Res; 1999 Jun; 830(2):314-9. PubMed ID: 10366688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
    Faherty CJ; Raviie Shepherd K; Herasimtschuk A; Smeyne RJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):170-9. PubMed ID: 15790541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
    Sun M; Kong L; Wang X; Holmes C; Gao Q; Zhang GR; Pfeilschifter J; Goldstein DS; Geller AI
    Hum Gene Ther; 2004 Dec; 15(12):1177-96. PubMed ID: 15684695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
    Jourdain S; Morissette M; Morin N; Di Paolo T
    J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective alterations of gene expression in mice induced by MPTP.
    Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
    Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.